Clinical Trial Update: Extension Study for the Port Delivery System With Ranibizumab (Portal) [Phase 3]

View source ↗

Summary

Extension study for the Port Delivery System delivering ranibizumab for neovascular age-related macular degeneration is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Neovascular Age-Related Macular Degeneration | Phase 3 | Status: RECRUITING